Section Summary

Antibody, payload, and linker are typically evaluated as three separate technical questions. For CEACAM5, treating them independently produces a materially wrong read on an asset’s commercial potential. Together they form a single strategic architecture: the antibody determines where and how efficiently an ADC binds and internalizes; the payload determines how much biological effect it generates and whether neighboring low-expressing cells can also be killed; the linker determines whether the payload reaches the tumor intact, in an appropriate form, at an acceptable systemic exposure. These properties propagate directly into diagnostics, patient eligibility, trial design, combination strategy, and ultimately addressable market — which is why architecture, not target biology alone, is where CEACAM5 commercial leadership will actually be decided.

The market has already reached a version of this conclusion by other means: several billion dollars in ADC acquisitions and platform licenses over the past three years — Pfizer/Seagen, Genmab/ProfoundBio, BMS/Orum, Lonza/Synaffix — have each cited reusable technology, not just the assets acquired, as part of the rationale. Standard due diligence for a CEACAM5 asset has not caught up to that reality. Patent estate and addressable population remain the default screen, but CEACAM5 patents are not a strong barrier to entry, and the addressable population itself is directional rather than fixed — moving from an estimated 90,000 patients per year under current architecture toward a ceiling of roughly 500,000 as diagnostics and architecture jointly expand what current strategies reach (assumptions detailed in Section 1; diagnostic pathways in Section 9).

This section applies four Decision Tests — population expansion, white-space expansion, treatment strategy, and leadership/1L potential — to turn that principle into a usable evaluation framework, and points to the due diligence checklists in Section 6 (Antibodies), Section 7 (Payloads) and Section 8 (Linkers) as the tool for applying it to a specific asset. Test 4 (leadership / 1L potential) is expanded in Section 10. The objective throughout is not a fixed valuation for any single molecule. It is a set of principles, the architectural modifications that follow from them, and the rationale for making those modifications — the basis on which a CEACAM5 acquisition, license, or internal investment decision should actually be made.